AUS
NZ
UK
CA
USA
IND
Highlights
- New portfolio of AI-engineered proteins designed to enhance cell culture and cellular therapy.
- FGF basic Heat Stable available in both RUO and GMP formats, broadening research and therapeutic uses.
- Innovative proteins feature enhanced functionalities, including hyperactivity, receptor affinities, and heat stability.
Bio-Techne (NASDAQ:TECH) has announced the launch of a new suite of AI-engineered designer proteins through its R&D Systems brand. This expanded portfolio includes cutting-edge proteins such as IL-2 Heat Stable Agonist, Activin A Hyperactive, FGF basic Heat Stable (offered in both Research Use Only (RUO) and Good Manufacturing Practice (GMP) formats), and three Wnt/RSPO Agonist proteins. These proteins, developed using advanced AI-based design platforms and protein evolutionary workflows, are poised to enhance cellular therapy processes and accelerate various research applications.
The new protein products are engineered to address key challenges in cellular therapy, stem cell research, organoid development, and regenerative medicine. The proteins feature several enhancements, such as hyperactivity, improved receptor affinities, and better heat stability. These improvements are critical for optimizing cell culture performance and enabling more efficient, scalable solutions in therapeutic and research settings. The design of these proteins benefits from generative AI, which has been trained on nearly five decades of Bio-Techne’s leadership in proteomics, allowing for more precise and effective protein engineering.
Among the highlights of this launch is the availability of the FGF basic Heat Stable protein in both RUO and GMP formats. This dual availability makes the protein suitable for both laboratory research and clinical therapeutic applications. By offering these proteins in GMP format, Bio-Techne is positioning its new products to support the transition from basic research to clinical development, facilitating the broader adoption of cellular therapies.
These newly developed AI-engineered proteins are expected to address critical needs in several key areas of biomedical research and therapy. In cellular therapy, the enhanced protein functionality can improve the efficiency and effectiveness of therapeutic cell cultures. In stem cell research and organoid development, the proteins can help optimize conditions for cell growth and differentiation, thereby advancing these fields. Additionally, regenerative medicine applications stand to benefit from the improved protein stability and performance, enabling more reliable and scalable solutions.
Bio-Techne’s use of AI-based design to engineer these proteins marks a significant innovation in the biotech field. With the ability to generate proteins that are more stable, functional, and optimized for specific applications, the company is pushing the boundaries of what is possible in the development of therapeutic and research tools. By combining decades of proteomic expertise with advanced artificial intelligence, Bio-Techne is setting a new standard for precision protein engineering.
